Cargando…

Thrombopoietin is required for full phenotype expression in a JAK2(V617F) transgenic mouse model of polycythemia vera

The myeloproliferative neoplasms, polycythemia vera, essential thrombocytosis and primary myelofibrosis are hematopoietic stem cell disorders and share driver mutations that either directly activate the thrombopoietin receptor, MPL, or activate it indirectly through gain-of-function mutations in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spivak, Jerry L., Merchant, Akil, Williams, Donna M., Rogers, Ophelia, Zhao, Wanke, Duffield, Amy, Resar, Linda S., Moliterno, Alison R., Zhao, Zhizhuang J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263591/ https://www.ncbi.nlm.nih.gov/pubmed/32479500 http://dx.doi.org/10.1371/journal.pone.0232801

Ejemplares similares

JAK2(V617F) allele burden in polycythemia vera: burden of proof
por: Moliterno, Alison R., et al.
Publicado: (2023)

JAK2 V617F and the evolving paradigm of polycythemia vera
por: Means, Robert T.
Publicado: (2010)

Sigmoid Venous Thrombosis in JAK2 V617F Mutated Polycythemia Vera
por: Martins De Oliveira Filho, Cilomar, et al.
Publicado: (2022)

Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice
por: Shi, Kaiyao, et al.
Publicado: (2014)

Cerebral venous sinus thrombosis in polycythemia vera patients with JAK2V617F mutation
por: Shen, Hui-Xin, et al.
Publicado: (2021)

Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera
por: Liu, Dan, et al.
Publicado: (2021)

JAK2 V617F-positive polycythemia vera accompanied by renal artery stenosis
por: Kim, Jae Young, et al.
Publicado: (2014)

CD169(+) macrophages provide a niche promoting erythropoiesis under homeostasis, myeloablation and in JAK2V617F-induced polycythemia vera
por: Chow, Andrew, et al.
Publicado: (2013)

JAK2 Negative Polycythemia Vera
por: Geetha, J P, et al.
Publicado: (2010)

Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms
por: Stein, Brady L., et al.
Publicado: (2011)

The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN
por: Spivak, Jerry L., et al.
Publicado: (2021)

Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values
por: Silver, Richard T., et al.
Publicado: (2019)

Absence of JAK2 V617F-mutated polycythemia vera in obstructive sleep apnea-associated erythrocytosis
por: Langabeer, Stephen E.
Publicado: (2022)

JAK2 p.V617F Variants in Non-Blood DNA from Patients with Polycythemia Vera
por: Mori, Naoki, et al.
Publicado: (2023)

Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden
por: Lee, A-Jin, et al.
Publicado: (2021)

PB2178: EVALUATION OF JAK2 EXON 12 MUTATIONS IN PATIENTS WITH JAK2 (V617F)-NEGATIVE POLYCYTHEMIA VERA
por: Khosravi, Sahar, et al.
Publicado: (2023)

Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET)
por: Zhao, Shixiang, et al.
Publicado: (2016)

Emergence of BCR-ABL1 Chronic Myeloid Leukemia in a JAK2-V617F Polycythemia Vera
por: Lorenzo, Mariana, et al.
Publicado: (2020)

Generation and Characterization of a JAK2V617F-Containing Erythroleukemia Cell Line
por: Zhao, Wanke, et al.
Publicado: (2014)

Hereditary hemochromatosis and JAK2‐positive polycythemia vera
por: Radwan, Ahmed, et al.
Publicado: (2021)

JAK2 and TET2 Mutation in Polycythemia Vera
por: Padda, Jaskamal, et al.
Publicado: (2021)

Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo
por: Verger, Emmanuelle, et al.
Publicado: (2018)

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study
por: Vannucchi, Alessandro Maria, et al.
Publicado: (2017)

JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomes
por: Sureau, Léa, et al.
Publicado: (2022)

Association of polycythemia vera with positive JAK2V617F mutation and myasthenia gravis: A report of two cases
por: Sasi, Sreethish, et al.
Publicado: (2020)

JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines
por: Zhao, Wanke, et al.
Publicado: (2012)

PB2192: JAK2 V617F ALLELE BURDEN AND THROMBOTIC EVENTS IN PATIENTS WITH JAK2 V617F POSITIVE POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA AT HIGH RISK OF THROMBOSIS
por: Hwang, Yun Hui, et al.
Publicado: (2023)

Influence of JAK2V617F allele burden on clinical phenotype of polycythemia vera patients: A study from India
por: Sazawal, Sudha, et al.
Publicado: (2019)

JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis
por: Guglielmelli, Paola, et al.
Publicado: (2021)

Genetic Knock-out of TNFR1 and TNFR2 in a JAK2-V617F Polycythemia Vera Mouse Model
por: Müller, Peter, et al.
Publicado: (2022)

JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome
por: Kanduła, Zuzanna, et al.
Publicado: (2022)

Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera
por: Bjørn, M.E., et al.
Publicado: (2014)

Development and Inter-Laboratory Validation of Unlabeled Probe Melting Curve Analysis for Detection of JAK2 V617F Mutation in Polycythemia Vera
por: Wu, Zhiyuan, et al.
Publicado: (2011)

Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib
por: Zhou, A, et al.
Publicado: (2015)

JAK2 V617F as a Marker for Long-Term Disease Progression and Mortality in Polycythemia Vera and its Role in Economic Modeling
por: Hjelmgren, Jonas, et al.
Publicado: (2020)

JAK2V617F positive polycythemia vera with paroxysmal nocturnal hemoglobinuria and visceral thromboses: a case report and review of the literature
por: Chatzidavid, Sevastianos, et al.
Publicado: (2021)

Central Nervous System Lymphoma Harboring the JAK2 V617F Mutation That Developed after a 20-year History of Polycythemia Vera
por: Kajikawa, Natsuki, et al.
Publicado: (2018)

Data‐driven analysis of JAK2V617F kinetics during interferon‐alpha2 treatment of patients with polycythemia vera and related neoplasms
por: Pedersen, Rasmus K., et al.
Publicado: (2020)

Case report: Double L611S/V617L JAK2 mutation in a patient with polycythemia vera originally diagnosed with essential thrombocythemia
por: Li, Xiao-qing, et al.
Publicado: (2022)

Development of a highly sensitive method for detection of JAK2V617F
por: Zhao, Anna H, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_vfa0rk7pp8eajv0g15qvnh0ueh